



NGS proteomics platform for biomarker discovery and validation

Biotechnology Sector: Life science Tools/Deep Tech / AI

Dr. Gregory Penner, Founder & President
September 2026



The current pain points for biomarker discovery

Protein



Changes to proteins
cause disease.

Biomarkers need to be
discovered and
validated for every
disease



Disease

Constraints to biomarker discovery

1.) CapEx

- All platforms require expensive, dedicated equipment

2.) Scalability (samples processed/day)

- Significant limitation for mass spec

3.) Protein diversity

- NGS based affinity platforms are limited to panels of canonical proteins
- Only 1% of all possible protein isoforms can be measured



The Aptamarker Platform is the solution

High-Plex Platform

268 million probes, 428 thousand structures in each sample

Biomarker discovery

Agnostic nature, not built on panels of known proteins.

No CAPEX

Uses standard lab equipment.

Characterizes protein modifications

Includes PTMs, cleavage and protein mis-folding

NGS-based

Output as NGS readouts

Protein diversity

Enables deep data on the whole proteome

Works with all species


Human, animal, plant, yeast.

Broad AI applications


*Integration in multi-omics
Deep data suitable for machine learning
Discovery of patterns*

Scalability

*Automated workflow
Thousands of samples/day*




Business model: Kit sales & Software licensing



NVBE

End user




Competitive advantage


	Required CapEx >300K	Number of probes	COGS	Path to IVD or LDT with platform probes	Species targeted	Detectable Protein isoforms / PTMs	Nature of probes	Cost per sample
	Yes	10800	High	No	Human (primary) / Mouse (Limited)	Very Limited	Antibody pairs for each protein	~\$200– \$500/sample
	Yes	11000	High	No	Human (primary) / Mouse (Limited)	Very Limited	SOMAmer® (modified aptamers)	~\$500– \$800/sample
	Yes	800	High	Yes (very limited)	Human (primary) / Mouse (Limited)	Very Limited	Attobody™ (proprietary Antibodies)	~\$200– \$500/sample
	No	428 686	Low	Yes	All species	Unlimited	Native DNA aptamers	90€



Why now? The market is ready



Reported Gross annual revenue



Why will Aptamarkers dominate this market?

1.) Single library design = lower cost of goods

- We can support higher scale while maintaining profit

2.) Capacity to predict protein abundance


- We predict protein abundance the same as our competitors.
- We expand the platform by ML algorithms not more probes.

3.) Greater depth

- More probes means more proteins
- Capture structural isoforms of all proteins
- Discover new biomarkers
- Capacity to detect all proteins predicted by AlphaFold3



Aptamarkers Connects AlphaFold 3 In-Silico Structural Modeling with Real World Patient Biomarker Detection



Go to market strategy

Life Science Tools Market: **150B € 2024**

TAM : Proteomics market: **33B € 2024**

SAM: Current NGS-Based Proteomics Market : **500M € 2024**

SOM: Projected Aptamarker revenue: **74M € 2030**

End users (Research use only)

1. Academics (R&D)

Research institutions and Universities conducting basic and applied research.
50.000 PIs/100 samples/year each

2. Research Consortia

Grant funded groups of researchers within a discipline
1.000 consortia/~1.000 samples/year each

Pharmaceutical and biotechnology companies engaged in drug development, and biomarker research.

3. Contract Research Organizations (CROs) and Pharmaceutical companies

Organizations involved in clinical trials
500 companies/~10.000 samples/year each

4. Biobanks

National or disease specific biobanks of patient samples
100 Biobanks/~100.000 samples/year each

Early adopters

Late adopters



Traction/Validation

Co-development agreements: 4

Patents: 5

Publications: 4

Strategic Alliance with Pharma



Authorized Service Providers



European Distribution Agreement



IP Licensed



EU Horizon grant



Pilot Projects



Meet the team



Co-founder & President

Gregory Penner

Wheat Genomics Lead,
Monsanto.
Experience commercializing
innovation
Biostatistics 30 y
Senior entrepreneur – 3
companies



Co-founder

Ximena Vedoya

Regulatory affairs,
Monsanto.
Molecular Biology/Business
Strategy management 25 y
Senior entrepreneur – 3
companies



Business Development

Jérémie Thiblet

Life Sciences Industry 24 y
C-level roles in diagnostics
startups.



Lab Manager

Soizic Lecocq

10 years of experience with
NVB Europe.
Expert with the
development of the
Aptamarker Platform and
technology transfer.



Senior Bioinformatician

Chloe Mansour

3 years of experience with
NVB
Expert in Aptamer Library
Design and Machine
Learning implementation



We are raising 5M€ in Round A

2026

Seed 2M €

- Invented platform
- Platform and prototype validation
- Foundation of IP
- Development of commercial kit
- First sales of product

2028

Round A 5M €

- Prediction of 10.000 proteins
 - Increase bioinformatics and wet lab capacity
 - Purchase samples and contract mass spec analysis
- Commercialize software
 - Panels by disease
 - Structural isoforms
 - Patient stratification
- Build sales team
- Build management team

2031

Round B 50M €

- Increase revenue on kit sales to >10M/year
- Increase revenue on software licences to >2M/year
- Develop capacity for unlimited AI based prediction of protein identities

M&A
2B €

- Alamar, IPO 1.9B € (20X)
- Olink purchased by Thermo Fisher 3.1B (15X)
- BioTechne purchase by Merck, 9.9B (9.4X)
- Target M&A
 - Novartis
 - Sanofi
 - BioRad
 - Servier
 - Roche
 - Danaher

24 month runway to Round B



Thank You
neoventures-eu.com

Dr. Gregory Penner, Founder & President
September 2026

